Sorafenib-Induced Liver Failure: A Case Report and Review of the Literature
In patients with hepatocellular carcinoma characterized by vascular invasion and/or extrahepatic disease, Sorafenib is considered treatment of choice. Although mild liver test abnormalities were reported in less than 1% of the patients in the two large randomized, controlled phase III trials, four...
Saved in:
Main Authors: | Anneleen Van Hootegem, Chris Verslype, Werner Van Steenbergen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2011-01-01
|
Series: | Case Reports in Hepatology |
Online Access: | http://dx.doi.org/10.1155/2011/941395 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Successful Treatment of Crizotinib-Induced Fulminant Liver Failure: A Case Report and Review of Literature
by: Kyle Kreitman, et al.
Published: (2020-01-01) -
Sorafenib as Adjuvant Therapy Post–Liver Transplant: A Single-center Experience
by: Hala Hassanain, MD, et al.
Published: (2025-02-01) -
Use of Adjuvant Sorafenib in Liver Transplant Recipients with High-Risk Hepatocellular Carcinoma
by: Kirti Shetty, et al.
Published: (2014-01-01) -
Pifithrin-μ sensitizes mTOR-activated liver cancer to sorafenib treatment
by: Jiarui Lv, et al.
Published: (2025-01-01) -
Acute Liver Failure Caused by ‘Fat Burners’ and Dietary Supplements: A Case Report and Literature Review
by: Y Radha Krishna, et al.
Published: (2011-01-01)